Literature DB >> 28025362

Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus.

Benjamin J Morasco1,2,3, David W Greaves2,3, Travis I Lovejoy4,2,3, Dennis C Turk5, Steven K Dobscha4,2,3, Peter Hauser6,7,8.   

Abstract

OBJECTIVE: Individuals with the hepatitis C virus (HCV) have high rates of both chronic pain and substance use disorder (SUD). Despite high comorbidity, there are limited data available on effective methods of treatment for co-occurring chronic pain and SUD. In this study, we sought to develop and conduct preliminary testing of an integrated cognitive-behavior therapy (CBT) for chronic pain and SUD in patients with HCV.
DESIGN: Descriptive, including pretreatment, posttreatment, and follow-up testing. SETTING AND PATIENTS: Outpatient clinic as part of one VA Medical Center. PARTICIPANTS: Veterans with chronic pain, SUD, and HCV. INTERVENTION: Eight-session integrated group CBT for chronic pain and SUD in patients with HCV.
METHODS: Participants completed standardized measures of pain, function, depression severity, and alcohol and substance use at baseline, post-treatment, and 3-month follow-up.
RESULTS: Generalized estimating equations identified improvements in pain interference, reducing cravings for alcohol and other substances, and decreasing past-month alcohol and substance use. The proportion of participants who met diagnostic criteria for current SUD demonstrated a four-fold decrease over the course of the study from 24% at baseline to 15% at post-treatment and 6% at 3-month follow-up. On response to a global impression of change, 94% of participants noted improvement from baseline.
CONCLUSIONS: Results from this pilot study suggest that a customized CBT for patients with both chronic pain and SUD (CBT-cp.sud) may be beneficial in improving important pain and addiction-related outcomes in patients with HCV. Larger scale investigations of this intervention appear warranted. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. 2016. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  Chronic Pain; Cognitive-Behavior Therapy; Hepatitis C Virus; Integrated Treatment; Substance Use Disorder

Mesh:

Year:  2016        PMID: 28025362      PMCID: PMC6280937          DOI: 10.1093/pm/pnw076

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  36 in total

1.  Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain.

Authors:  Einat Peles; Shaul Schreiber; Jacob Gordon; Miriam Adelson
Journal:  Pain       Date:  2005-02       Impact factor: 6.961

2.  Association between substance use disorder status and pain-related function following 12 months of treatment in primary care patients with musculoskeletal pain.

Authors:  Benjamin J Morasco; Kathryn Corson; Dennis C Turk; Steven K Dobscha
Journal:  J Pain       Date:  2010-09-20       Impact factor: 5.820

3.  Psychometric properties of the Penn Alcohol Craving Scale.

Authors:  B A Flannery; J R Volpicelli; H M Pettinati
Journal:  Alcohol Clin Exp Res       Date:  1999-08       Impact factor: 3.455

4.  Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.

Authors:  Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

5.  Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Margaret L Griffin; R Kathryn McHugh; Deborah Haller; Petra Jacobs; John Gardin; Dan Fischer; Kristen D Rosen
Journal:  J Subst Abuse Treat       Date:  2014-04-04

6.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

7.  Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C.

Authors:  Melissa H Adams; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser; Benjamin J Morasco
Journal:  Gen Hosp Psychiatry       Date:  2015-07-17       Impact factor: 3.238

8.  Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities.

Authors:  Jennifer Sharpe Potter; Kristi Prather; Roger D Weiss
Journal:  Am J Addict       Date:  2008 Mar-Apr

9.  Outcome from integrated pain management treatment for recovering substance abusers.

Authors:  Shawn R Currie; David C Hodgins; Ann Crabtree; Jacquie Jacobi; Susan Armstrong
Journal:  J Pain       Date:  2003-03       Impact factor: 5.820

10.  Persistent pain is associated with substance use after detoxification: a prospective cohort analysis.

Authors:  Mary Jo Larson; Michael Paasche-Orlow; Debbie M Cheng; Christine Lloyd-Travaglini; Richard Saitz; Jeffrey H Samet
Journal:  Addiction       Date:  2007-05       Impact factor: 6.526

View more
  11 in total

1.  An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Lynn M Madden; Christopher Liong; Joel Ginn; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2018-11-13       Impact factor: 4.492

2.  Opioid use disorder with chronic pain increases disease burden and service use.

Authors:  R Ross MacLean; Mehmet Sofuoglu; Elina Stefanovics; Robert Rosenheck
Journal:  Psychol Serv       Date:  2021-12-30

3.  Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy.

Authors:  Shannon M Nugent; Bobbi Jo Yarborough; Ning X Smith; Steven K Dobscha; Richard A Deyo; Carla A Green; Benjamin J Morasco
Journal:  Gen Hosp Psychiatry       Date:  2017-11-08       Impact factor: 3.238

4.  Chronic non-cancer pain among adults with substance use disorders: Prevalence, characteristics, and association with opioid overdose and healthcare utilization.

Authors:  William S John; Li-Tzy Wu
Journal:  Drug Alcohol Depend       Date:  2020-02-11       Impact factor: 4.492

5.  Clinician Response to Aberrant Urine Drug Test Results of Patients Prescribed Opioid Therapy for Chronic Pain.

Authors:  Benjamin J Morasco; Erin E Krebs; Melissa H Adams; Stephanie Hyde; Janet Zamudio; Steven K Dobscha
Journal:  Clin J Pain       Date:  2019-01       Impact factor: 3.442

6.  Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test.

Authors:  Shannon M Nugent; Steven K Dobscha; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Joseph W Frank; Travis I Lovejoy
Journal:  J Gen Intern Med       Date:  2017-06-09       Impact factor: 5.128

7.  Patients' perceptions of the pathways linking chronic pain with problematic substance use.

Authors:  Jessica J Wyse; Jennette Lovejoy; Julia Holloway; Benjamin J Morasco; Steven K Dobscha; Hildi Hagedorn; Travis I Lovejoy
Journal:  Pain       Date:  2021-03-01       Impact factor: 7.926

8.  Pain Diagnosis, Pain Coping, and Function in Individuals with Chronic Musculoskeletal Pain.

Authors:  Alexandra Ferreira-Valente; Inês Queiroz-Garcia; José Pais-Ribeiro; Mark P Jensen
Journal:  J Pain Res       Date:  2020-04-22       Impact factor: 3.133

9.  A Pilot Investigation of Nonpharmacological Pain Management Intervention Groups in Methadone Maintenance Treatment.

Authors:  Kimberly A DiMeola; Jeff Haynes; Meredith Barone; Mark Beitel; Lynn M Madden; Christopher J Cutter; Anthony Raso; Marina Gaeta; Xiaoying Zheng; Declan T Barry
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

10.  A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference.

Authors:  William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.